Kyntra Bio, Inc. Non-Employee Director Compensation Policy

This Non-Employee Director Compensation Policy (the “Policy”) documents the terms and conditions of the cash and equity compensation that non-employee members of the Board of Directors (the “Board”) of Kyntra Bio, Inc. (“Kyntra Bio”) may earn for their service on the Board from and after the initial public offering of the common stock of Kyntra Bio.

Eligible Directors

Only members of the Board who are not concurrently employees of Kyntra Bio are eligible for compensation under this Policy (each such member, a “Director”). Any director may also decline compensation per policy of their affiliated entity or for any other reason prior to the start of the period of service to which the compensation relates.

Annual Cash Compensation

The annual cash compensation set forth below is payable in equal quarterly installments, in arrears, on the last day of each quarter in which the service occurred, pro-rated for any partial quarters of service. All annual cash fees are vested upon payment.

1. Annual Board Service Retainer:

…

---

Exhibit 10.1

STANDARD LEASE AGREEMENT

FOR OFFICE/WAREHOUSE SPACE

THIS LEASE AGREEMENT (hereafter called the "Lease Agreement") made as of the 1st day of April, 2026, by and between NORTHCROSS WEST INDUSTRIAL OWNER, LLC, a Delaware limited liability company having offices at c/o United Properties Investment LLC, 250 Nicollet Mall, Suite 500, Minneapolis, Minnesota 55401 (hereafter called the "Landlord") and ANTERIS TECHNOLOGIES CORPORATION, a Minnesota corporation (hereafter called the "Tenant").

ARTICLE 1.

DESCRIPTION OF PREMISES

…

CREDIT AGREEMENT

DATED AS OF MAY 7, 2026

AMONG

OPTIMIZERX CORPORATION

as Borrower,

THE OTHER LOAN PARTIES FROM TIME TO TIME PARTY HERETO,

as Loan Parties,

FIFTH THIRD BANK, NATIONAL ASSOCIATION,

as Agent, L/C Issuer and Swing Line Lender,

THE LENDERS FROM TIME TO TIME PARTY HERETO,

and

FIFTH THIRD BANK, NATIONAL ASSOCIATION,

as Sole Lead Arranger and Sole Bookrunner

TABLE OF CONTENTS

Page

1.1.    Certain Defined Terms    1

1.2.    Accounting Terms and Determinations    35

1.3.    Other Definitional Provisions and References    36

2.    ADVANCES AND LETTERS OF CREDIT    36

2.1.    Revolving Credit Advances, Term Loan, and Borrowings    36

2.2.    Prepayments/Commitment Termination    37

2.3.    Swing Line Advances    39

…

[Certain information contained in this exhibit has been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K, as indicated with the notation “[***]”, because such information is both not material and is the type that the registrant treats as private or confidential.

Certain schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. Orchestra BioMed Holdings, Inc. agrees to furnish supplementally a copy of any omitted schedule or exhibit to the Securities and Exchange Commission upon request.]

Execution Version

THIRD AMENDMENT

TO

LOAN AND SECURITY AGREEMENT

​

…

​

Exhibit 10.1

[Certain information contained in this exhibit has been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K, as indicated with the notation “[***]”, because such information is both not material and is the type that the registrant treats as private or confidential.

In addition, certain information contained in this exhibit has been redacted pursuant to Item 601(a)(6) of Regulation S-K, as indicated with the notation “[###]”, because disclosure of such information would constitute a clearly unwarranted invasion of personal privacy.

Certain schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. Orchestra BioMed Holdings, Inc. agrees to furnish supplementally a copy of any omitted schedule or exhibit to the Securities and Exchange Commission upon request.]

Execution Version

FIRST AMENDMENT

TO

LOAN AND SECURITY AGREEMENT

​

…

OKLO INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”) is made as of __________ by and between Oklo Inc., a Delaware corporation (the “Company”), and __________ (“Indemnitee”). RECITALS The Company and Indemnitee recognize the increasing difficulty in obtaining liability insurance for directors, officers and key employees, the significant increases in the cost of such insurance and the general reductions in the coverage of such insurance. The Company and Indemnitee further recognize the substantial increase in corporate litigation in general, subjecting directors, officers and key employees to expensive litigation risks at the same time as the availability and coverage of liability insurance has been severely limited. Indemnitee does not regard the current protection available as adequate under the present circumstances, and Indemnitee may not be willing to continue to serve in Indemnitee’s current capacity with the Company without additional protection. The Company desires to attract and retain the services of highly qualified indiv

…

January 13, 2026

Mayo Pujols via email to […***…]

Re: Employment Terms

Dear Mayo:

Kyverna Therapeutics, Inc. (the “Company”) is pleased to offer you employment beginning on February 9, 2026 (the “Start Date”); provided, however, if your employment does not commence on the Start Date, this letter shall be null and void and without force or effect.

Position

Your position will be Chief Technology Officer of the Company with responsibilities, duties, and authority as usual and customary for such position, reporting to the Company’s Chief Executive Officer and Executive Chairperson of the Board of Directors (the “Board”). You will work on a hybrid (remote and Company office) basis. The Company may change your position, duties, and work location from time to time in its discretion, subject to the severance protections outlined below.

…

FOURTH AMENDMENT TO CREDIT AGREEMENT

This FOURTH AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is made and entered into as of March 26, 2026 by and among TRISALUS OPERATING LIFE SCIENCES, INC., a Delaware corporation (the “Borrower”), TRISALUS LIFE SCIENCES, INC., a Delaware corporation (the “Parent”), the Lenders party hereto (the “Lenders”) and ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP, as administrative agent for the Lenders (in such capacity, and together with its Affiliates, successors, transferees and assignees, the “Administrative Agent”).

…

EMPLOYMENT AGREEMENT

This Employment Agreement (this “Agreement”) is entered into as of April 29, 2026 (the “Effective Date”) by and between iAnthus Capital Management, LLC, including iAnthus Capital Holdings, Inc. and all of its subsidiaries (the “Company”), and Jason Ware, an individual (“Executive”) (the Company and Executive each a “Party” and, collectively, the “Parties”).

W I T N E S E T H:

WHEREAS, the Company wishes to employ Executive, and Executive wishes to be employed by the Company, in each case, on the terms and conditions set forth herein.

NOW, THEREFORE, in consideration of the mutual covenants and undertakings herein contained, the Company agrees to employ Executive, and Executive accepts employment with the Company, on the terms and conditions set forth in this Agreement, to which the Parties agree as follows:

…

NKARTA, INC.

DIRECTOR COMPENSATION POLICY

(Last Amended March 14, 2025)

Directors of Nkarta, Inc., a Delaware corporation (the “Company”), who are not employed by the Company or one of its subsidiaries (“Non-Employee Directors”) are entitled to the compensation set forth below for their service as a member of the Board of Directors (the “Board”) of the Company. The Board (or any committee of the Board within the authority delegated to it) has the right to amend this policy from time to time.

Cash Compensation

Annual Retainer	$40,000
Additional Board Chair/Lead Independent Director Retainer	$30,000
Additional Committee Chair Retainers:
Audit Committee Chair	$15,000
Compensation Committee Chair	$12,000
Nominating and Governance Committee Chair	$10,000
Science and Technology Committee Chair	$12,000
Additional Committee Retainers:
Audit Committee	$7,500
Compensation Committee	$6,000
Nominating and Governance Committee	$5,000
Science and Technology Committee	$6,000

…

CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

AMENDMENT NO. 3 TO LICENSE AGREEMENT

This AMENDMENT NO. 3 TO LICENSE AGREEMENT (the “Amendment No. 3”)

made and effective as of March 27, 2026 (the “Amendment No. 3 Effective Date”), is by and between Immunome, Inc., a Delaware corporation with offices at 18702 N Creek Parkway South, Suite #100, Bothell, WA 98011 (“Immunome”) and Bristol-Myers Squibb Company, a Delaware corporation with office at Route 206 and Province Line Road, Princeton, New Jersey 08543 (“BMS”). Immunome and BMS are together referred to in this Amendment No. 3 as the “Parties” and individually as a “Party.”

Background:

…

EXHIBIT 10.1 CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS (I) NOT MATERIAL, AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMISSIONS ARE MARKED [*****]. Execution Version AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT OF NEOGENYX FUELS LLC DATED AS OF May 12, 2026 THE UNITS REPRESENTED BY THIS AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT HAVE NOT BEEN REGISTERED UNDER APPLICABLE SECURITIES LAWS. SUCH UNITS MAY NOT BE SOLD, ASSIGNED, PLEDGED OR OTHERWISE DISPOSED OF AT ANY TIME WITHOUT EFFECTIVE REGISTRATION UNDER SUCH LAWS OR EXEMPTIONS THEREFROM. THE UNITS ARE ALSO SUBJECT TO ADDITIONAL RESTRICTIONS ON TRANSFER SPECIFIED IN THIS AGREEMENT, AND NEOGENYX FUELS LLC, RESERVES THE RIGHT TO REFUSE THE TRANSFER OF SUCH UNITS UNLESS AND UNTIL SUCH CONDITIONS HAVE BEEN FULFILLED WITH RESPECT TO ANY TRANSFER. A COPY OF THIS AGREEMENT SHALL BE PROMPTLY FURNISHED BY NEOGENYX FUELS LLC, TO THE HOLDER OF ANY UNITS UPON WRITTEN REQUEST AND WITHOUT CHARGE.

---

…